About this trial
Chronic obstructive pulmonary disease (COPD) is a progressive lung disease characterized by persistent airflow obstruction and chronic respiratory symptoms or alpha-1-antitrypsin deficiency in response to inhaled cigarette smoke or other irritants. The excessive morbidity and mortality associated with COPD acute exacerbations represent a significant public health problem that places a high burden on patients, their families and society. In frequent and severe exacerbations, patients may experience a decrease in quality of life, depression, and even death up to one year after hospitalization. Costs associated with COPD are more than $15.5 billion, and hospitalizations and repeated hospital admissions related to acute exacerbations alone account for 70% of all costs. For these reasons, efforts to reduce hospital admissions and hospitalizations associated with recurrent exacerbations are imperative to improve patient's quality of life and reduce the societal burden.
Eligibility criteria
Qualifiers
Being diagnosed with stage 4 (group D) COPD according to GOLD criteria
Being 18 years or older,
Having a video computer, tablet or phone,
Having an internet connection at home or on the phone,
Disqualifiers
Being illiterate,
Being diagnosed with first, second and third-stage COPD according to GOLD criteria,
Having another lung disease in addition to COPD (Lung cancer-Asthma, etc.),
Having physical and/or mental disabilities,
Trial design
Treatments tested in this trial
- health education
- Mobile application (Creating a WhatsApp group):
- Telephone interview: